{"nctId":"NCT00097591","briefTitle":"A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention","startDateStruct":{"date":"2004-11"},"conditions":["Coronary Arteriosclerosis","Acute Coronary Syndromes"],"count":13619,"armGroups":[{"label":"Prasugrel","type":"EXPERIMENTAL","interventionNames":["Drug: Prasugrel"]},{"label":"Clopidogrel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel"]}],"interventions":[{"name":"Prasugrel","otherNames":["CS-747","LY640315","Effient","Efient"]},{"name":"Clopidogrel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A person who has been diagnosed with acute coronary syndrome and is to undergo a percutaneous coronary intervention.\n* A person who is of the legal age of 18 and is mentally competent to provide a signed written informed consent.\n* If a woman is of childbearing potential (i.e., before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control.\n\nExclusion Criteria:\n\n* A person who has had an ischemic stroke within the last 3 months or a hemorrhagic stroke at any time in the past.\n* A person who has active internal bleeding or has a history of a bleeding disorder.\n* Individuals who are at an increased risk of bleeding based on laboratory criteria evaluated by the treatment physician or on medication that can cause bleeding.\n* A person who has liver disease; for example, cirrhosis.\n* A person who has a condition such as alcoholism, mental illness, or is drug dependent.\n* A person who has cardiogenic shock, a refractory ventricular arrhythmia, or congestive heart failure (class IV).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke","description":"The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"469","spread":null},{"groupId":"OG001","value":"565","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"643","spread":null},{"groupId":"OG001","value":"781","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events","description":"TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but \\<5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"303","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)","description":"The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"399","spread":null},{"groupId":"OG001","value":"504","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"472","spread":null},{"groupId":"OG001","value":"588","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke","description":"The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"502","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"462","spread":null},{"groupId":"OG001","value":"573","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events","description":"The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"797","spread":null},{"groupId":"OG001","value":"938","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke","description":"The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"692","spread":null},{"groupId":"OG001","value":"822","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1731,"n":6741},"commonTop":["Percutaneous coronary intervention","Chest pain","Hypertension","Haematoma","Contusion"]}}}